Wedbush has adjusted its price target for Solid Biosciences (SLDB, Financial), reducing it to $17 from the previous $18 due to an increased number of shares. Despite this revision, the firm maintains an Outperform rating, expressing confidence in the company's progress. Notably, all major development timelines for Solid Biosciences are proceeding as scheduled.
The firm highlighted that Solid Biosciences plans to engage with the FDA this summer to explore accelerated approval options for SGT-003. Furthermore, the company aims to complete dosing 20 subjects by the fourth quarter of 2025. Wedbush remains encouraged by the initial results from the INSPIRE study, although it believes the current market valuation does not fully reflect the company's potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Solid Biosciences Inc (SLDB, Financial) is $16.33 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 530.63% from the current price of $2.59. More detailed estimate data can be found on the Solid Biosciences Inc (SLDB) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Solid Biosciences Inc's (SLDB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
